Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA

References

• Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis. 2003;62:722–7.
   PubMed Web of Science ®Google Scholar
• Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, et al. Progressive preclinical interstitial lung disease in rheuma-toid arthritis. Arch Intern Med. 2008;168:159–66.
   PubMedGoogle Scholar
• Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis. Increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford). 2007;46:350–7.
   Google Scholar
• Winthrop KL. Serious infections with antirheumatic therapy: are biologicals worse? Ann Rheum Dis. 2006;65\(Suppl 3):iii54–7.
   Google Scholar
• Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Ann Rheum. 2006;54:628–34.
   Google Scholar
• Evans RB, Ettensohn DB, Fawaz-Estrup F, Lally EV, Kaplan SR. Gold lung: recent developments in pathogenesis, diagnosis, and therapy. Semin Arthritis Rheum. 1987;16:196–205.
   PubMed Web of Science ®Google Scholar
• Negishi M, Kaga S, Kasama T, Hashimoto M, Fukushima T, Yamagata N, et al. Lung injury associated with bucillamine therapy. Ryumachi. 1992;32:135–9.
   PubMedGoogle Scholar
• McCurry J. Japan deaths spark concerns over arthritis drug. Lancet. 2004;363:461.
   PubMed Web of Science ®Google Scholar
• Carroll GJ, Thomas R, Phatouros CC, Atchison MH, Leslie AL, Cook NJ, et al. Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J Rheumatol. 1994;21:51–4.
   PubMed Web of Science ®Google Scholar
• Bartram SA. Experience with methotrexate-associated pneumo-nitis in northeastern England: comment on the article by Kremer et al. Arthritis Rheum. 1998;41:1327–8.
   PubMedGoogle Scholar
• Kremer JM, Alarck GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radio-graphic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40:1829–37.
   PubMed Web of Science ®Google Scholar
• Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol. 1995;22:1043–7.
   PubMed Web of Science ®Google Scholar
• Yazici Y, Sokka T, Kautiainen H, Swearingen C, Kulman I, Pincus T. Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis. 2005;64:207–11.
   PubMed Web of Science ®Google Scholar
• Swierkot J, Szechiliski J. Methotrexate in rheumatoid arthritis. Pharmacol Rep. 2006;58:473–92.
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Inoue E, Tanaka E, Nakajima A, Taniguchi A, Terai C, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). Mod Rheumatol. 2007;17:98–105.
   PubMedGoogle Scholar
• Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4:443–8.
   PubMedGoogle Scholar
• Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. Scand J Rheu-matol. 2007;36:172–8.
   Google Scholar
• Rajasekaran BA, Shovlin D, Lord P, Kelly CA. Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis. Rheumatology (Oxford). 2001;40:1022–5.
   PubMed Web of Science ®Google Scholar
• Ochi S, Harigai M, Mizoguchi F, Iwai H, Hagiyama H, Oka T, et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol. 2006;16:316–20.
   PubMedGoogle Scholar
• Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004;45:93–104.
   PubMed Web of Science ®Google Scholar
• Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003;361:137–9.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci. 2007;52:1481–4.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Tan-iguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheu-matoid arthritis. Arthritis Rheum. 2003;49: 784–8.
   Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
   PubMed Web of Science ®Google Scholar
• Prevoo ML, van't Hof MA, van Leeuwen MA, van de Putte LB, Kuper HH, van Riel PL. Modified disease activity scores that include 28-joint counts. Development and validation in a pro-spective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38: 44–8.
   Google Scholar
• Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO. Pul-monary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum. 1987;16:186–95.
   Google Scholar
• Maskell NA, Waine DJ, Lindley A, Pepperell JC, Wakefield AE, Miller RF, et al. Asymptomatic carriage of Pneumocystis jiroveci in subjects undergoing bronchoscopy: a prospective study. Tho-rax. 2003;58:594–7.
   PubMed Web of Science ®Google Scholar
• Shimizu A, Oka H, Matsuda T, Ozaki S. (1-3)-beta-D glucan is a diagnostic and negative prognostic marker for Pneumocystis carinii pneumonia in patients with connective tissue disease. Clin Exp Rheumatol. 2005;23:678–80.
   PubMed Web of Science ®Google Scholar
• Roos JC, Chilvers ER, Ostor AJ. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2007;34: 238–9.
   Google Scholar
• Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infliximab therapy. J Rheumatol. 2006;33:1189–93.
   PubMed Web of Science ®Google Scholar
• Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol. 2004;33:221–7.
   Google Scholar
• Searles G, McKendry RJ. Methotrexate pneumonitis in rheuma-toid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987;14:1164–71.
   Google Scholar
• Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127:356–64.
   PubMed Web of Science ®Google Scholar
• Ohosone Y, Okano Y, Kameda H, Fujii T, Hama N, Hirakata M, et al. Clinical characteristics of patients with rheumatoid arthritis and methotrexate induced pneumonitis. J Rheumatol. 1997;24:2299–303.
   PubMed Web of Science ®Google Scholar
• Saag KG, Kolluri S, Koehnke RK, Georgou TA, Rachow JW, Hunninghake GW, et al. Rheumatoid arthritis lung disease. Determinants of radiographic and physiologic abnormalities. Arthritis Rheum. 1996;39:1711–9.
   PubMed Web of Science ®Google Scholar
• Scott TE, Wise RA, Hochberg MC, Wigley FM. HLA-DR4 and pulmonary dysfunction in rheumatoid arthritis. Am J Med. 1987;82:765–71.
   PubMed Web of Science ®Google Scholar
• Schernthaner G, Scherak O, Kolarz G, Kummer F. Seropositive rheumatoid arthritis associated with decreased diffusion capacity of the lung. Ann Rheum Dis. 1976;35:258–62.
   PubMed Web of Science ®Google Scholar
• Junk AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients. A radiological and clinical study. Scand J Rheumatol. 1982;11:217–24.
   Google Scholar
• Tuomi T, Heliiivaara M, Palosuo T, Aho K. Smoking, lung function, and rheumatoid factors. Ann Rheum Dis. 1990;49:753–6.
   PubMed Web of Science ®Google Scholar
• Popper MS, Bogdonoff ML, Hughes RL. Interstitial rheumatoid lung disease. A reassessment and review of the literature. Chest. 1972;62:243–50.
   Google Scholar
• Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest. 1988;93:114–8.
   PubMed Web of Science ®Google Scholar
• Davidson C, Brooks AG, Bacon PA. Lung function in rheumatoid arthritis. A clinic survey. Ann Rheum Dis. 1974;33:293–7.
   PubMedGoogle Scholar
• Lee HK, Kim DS, Yoo B, Seo JB, Rho JY, Colby TV, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associatedinterstitiallungdisease.Chest.2005;127:2019–27.
   PubMed Web of Science ®Google Scholar